

# David Adelstein

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1342718/publications.pdf>

Version: 2024-02-01

8  
papers

274  
citations

1478505

6  
h-index

1588992

8  
g-index

8  
all docs

8  
docs citations

8  
times ranked

502  
citing authors

#	ARTICLE	IF	CITATIONS
1	Failure rate in the untreated contralateral node negative neck of small lateralized oral cavity cancers: A multi-institutional collaborative study. <i>Oral Oncology</i> , 2021, 115, 105190.	1.5	6
2	Detection and Oncologic Outcomes of Head and Neck Squamous Cell Carcinoma of Unknown Primary Origin. <i>Anticancer Research</i> , 2020, 40, 4207-4214.	1.1	11
3	Low-Dose vs. High-Dose Cisplatin: Lessons Learned From 59 Chemoradiotherapy Trials in Head and Neck Cancer. <i>Frontiers in Oncology</i> , 2019, 9, 86.	2.8	71
4	Altered fractionation radiotherapy combined with concurrent low-dose or high-dose cisplatin in head and neck cancer: A systematic review of literature and meta-analysis. <i>Oral Oncology</i> , 2018, 76, 52-60.	1.5	29
5	Elucidation of salvage laryngectomy pathologic and clinical variables to guide further treatment intensification investigation. <i>Laryngoscope</i> , 2018, 128, 823-830.	2.0	17
6	Weekly Low-Dose Versus Three-Weekly High-Dose Cisplatin for Concurrent Chemoradiation in Locoregionally Advanced Non-Nasopharyngeal Head and Neck Cancer: A Systematic Review and Meta-Analysis of Aggregate Data. <i>Oncologist</i> , 2017, 22, 1056-1066.	3.7	122
7	Importance of residual primary cancer after induction therapy for esophageal adenocarcinoma. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2016, 152, 756-761.e5.	0.8	7
8	Pharmacotherapy of head and neck cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2015, 16, 2409-2422.	1.8	11